Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sets New 12-Month High – What’s Next?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.28 and last traded at $10.94, with a volume of 27479 shares changing hands. The stock had previously closed at $10.76.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

The firm has a market cap of $24.45 billion, a PE ratio of 52.11 and a beta of 0.86. The firm has a 50-day moving average price of $10.24 and a two-hundred day moving average price of $9.47. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The firm had revenue of $6.01 billion during the quarter. Research analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.